Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones

Aaron K. F. Wong; Allan D. Struthers; Anna Maria J. Choy; Chim C. Lang

doi:10.1016/j.hfc.2012.06.002

Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones

Aaron K. F. Wong, Allan D. Struthers, Anna Maria J. Choy, Chim C. Lang

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

Chronic heart failure (CHF) is an insulin-resistant (IR) state and the degree of IR is related to disease severity and poor clinical outcome in CHF. IR may be pathophysiologically linked with. Therefore, IR may represent a new target for treatment in CHF. Metformin and thiazolidinediones (TZDs) are effective diabetic therapies that are insulin sensitizers. TZDs are contraindicated in CHF because their use is associated with increased incidence of CHF as a result of their effects on renal sodium reabsorption and vascular permeability. There is evidence to suggest that metformin may be both safe and useful in CHF.

Original language	English
Pages (from-to)	539-50
Number of pages	12
Journal	Heart Failure Clinics
Volume	8
Issue number	4
DOIs	https://doi.org/10.1016/j.hfc.2012.06.002
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.hfc.2012.06.002

Cite this

@article{020362eb685941b8b6070c2ece72d39b,

title = "Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones",

abstract = "Chronic heart failure (CHF) is an insulin-resistant (IR) state and the degree of IR is related to disease severity and poor clinical outcome in CHF. IR may be pathophysiologically linked with. Therefore, IR may represent a new target for treatment in CHF. Metformin and thiazolidinediones (TZDs) are effective diabetic therapies that are insulin sensitizers. TZDs are contraindicated in CHF because their use is associated with increased incidence of CHF as a result of their effects on renal sodium reabsorption and vascular permeability. There is evidence to suggest that metformin may be both safe and useful in CHF.",

author = "Wong, {Aaron K. F.} and Struthers, {Allan D.} and Choy, {Anna Maria J.} and Lang, {Chim C.}",

year = "2012",

doi = "10.1016/j.hfc.2012.06.002",

language = "English",

volume = "8",

pages = "539--50",

journal = "Heart Failure Clinics",

issn = "1551-7136",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Insulin sensitization therapy and the heart

T2 - focus on metformin and thiazolidinediones

AU - Wong, Aaron K. F.

AU - Struthers, Allan D.

AU - Choy, Anna Maria J.

AU - Lang, Chim C.

PY - 2012

Y1 - 2012

N2 - Chronic heart failure (CHF) is an insulin-resistant (IR) state and the degree of IR is related to disease severity and poor clinical outcome in CHF. IR may be pathophysiologically linked with. Therefore, IR may represent a new target for treatment in CHF. Metformin and thiazolidinediones (TZDs) are effective diabetic therapies that are insulin sensitizers. TZDs are contraindicated in CHF because their use is associated with increased incidence of CHF as a result of their effects on renal sodium reabsorption and vascular permeability. There is evidence to suggest that metformin may be both safe and useful in CHF.

AB - Chronic heart failure (CHF) is an insulin-resistant (IR) state and the degree of IR is related to disease severity and poor clinical outcome in CHF. IR may be pathophysiologically linked with. Therefore, IR may represent a new target for treatment in CHF. Metformin and thiazolidinediones (TZDs) are effective diabetic therapies that are insulin sensitizers. TZDs are contraindicated in CHF because their use is associated with increased incidence of CHF as a result of their effects on renal sodium reabsorption and vascular permeability. There is evidence to suggest that metformin may be both safe and useful in CHF.

UR - http://www.scopus.com/inward/record.url?scp=84864739125&partnerID=8YFLogxK

U2 - 10.1016/j.hfc.2012.06.002

DO - 10.1016/j.hfc.2012.06.002

M3 - Article

C2 - 22999238

SN - 1551-7136

VL - 8

SP - 539

EP - 550

JO - Heart Failure Clinics

JF - Heart Failure Clinics

IS - 4

ER -

Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this